News
Portal’s Houston portfolio company, March Bio, announces Phase II trial
Portal’s portfolio company based in Houston, March Biosciences, recently announced their Phase 2 Clinical Trial of MB-105, First-in-Class CD5 CAR-T Cell Therapy for T-Cell Lymphoma
Get in touch
Chicago | Boston | Atlanta | Houston
©2025 Portal Innovations, LLC
Sign up for our monthly newsletter
Stay up-to-date on the latest VC, biotech, and med tech news in Chicago and across the U.S. Sign up with your email address below to get our monthly newsletter delivered to your inbox!